Immunocore Holdings Limited, an advanced stage biotechnology company, develops immunotherapies for the treatment of cancer, infectious and autoimmune diseases. The company is headquartered in Abingdon, the United Kingdom.
| Revenue (TTM) | $430.77M |
| Gross Profit (TTM) | $141.59M |
| EBITDA | 756,000 |
| Operating Margin | -2.58% |
| Return on Equity | -4.47% |
| Return on Assets | -0.16% |
| Revenue/Share (TTM) | $8.50 |
| Book Value | $8.15 |
| Price-to-Book | 3.87 |
| Price-to-Sales (TTM) | 3.67 |
| EV/Revenue | 2.739 |
| EV/EBITDA | 90.47 |
| Quarterly Earnings Growth (YoY) | 150.00% |
| Quarterly Revenue Growth (YoY) | 18.30% |
| Shares Outstanding | $51.50M |
| Float | $45.83M |
| % Insiders | 0.07% |
| % Institutions | 103.14% |
Volatility is currently contracting
IMCR achieves target enrollment in the phase III TEBE-AM study investigating Kimmtrak in previously treated patients with advanced melanoma.
Immunocore Holdings plc (IMCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK ® (tebentafusp) in previously treated advanced melanoma Topline overall survival data expected as early as end of 2026 (OXFORDSHIRE, England & CONSHOHOCKEN, PA & ROCKVILLE, MD, US, 14 September 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced the achievement of target patient enrollment (540 patients) in the TEBE-AM clinical trial (NCT05549297). TEBE-AM is a global, randomized, registrational Phase 3 clinical trial evaluating KIMMTRAK (tebentafusp) as monotherapy and in combination with pembrolizumab, versus Investigator's Choice, for the treatment of HLA-A*02:01-positive patients with advanced melanoma whose disease has progressed following prior therapy.
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 1 September 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced management will participate at the following conferences in September. Cantor Global Healthcare Conference 2026 Fireside Chat: Thursday, September 10, 2026, at 2:45 p.m.
Strong demand for Kimmtrak is fueling Immunocore's growth, while potential label expansion and late-2026 data could add further upside.
Immunocore's 3-month gain reflects Kimmtrak growth and pipeline progress, but valuation and mixed signals temper the momentum case.
Immunocore's Kimmtrak growth and late-stage catalysts strengthen its case, but a premium valuation and single-product risk raise the stakes.
Immunocore's Q2 revenue beat reflects strong Kimmtrak demand, but an EPS miss and distributor stocking headwind cloud the near-term outlook.
IMCR incurs wider-than-expected Q2 loss. However, revenues beat as sole drug Kimmtrak sales rise 18.3% year over year on higher U.S. and international sales.
The average of price targets set by Wall Street analysts indicates a potential upside of 77.9% in Immunocore (IMCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on IMCR and any ticker you trade — then tracks every position and per-strategy win rate.
